Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PBSCs + HA vs HA + Physio for Knee Cartilage Defects
NCT03101163Phase 2Completed
- Sponsor
- KLSMC Stem Cells
- Start
- Dec 2015
- Primary completion
- Jul 2022
- Modality
- Stem Cell Therapies
- Countries
- 2
01
Overview
Phase 2, randomised, open-label trial of autologous peripheral blood stem cell in articular cartilage injury (2 arms), sponsored by KLSMC Stem Cells. Primary endpoints: International Knee Documentation Committee Score at 24 months and Knee injury and Osteoarthritis Outcome Score pain subdomain at 24 months. Started Dec 2015; status: completed.
02
Drugs
autologous peripheral blood stem cell
03
Conditions
articular cartilage injury
Beyond the preview
Go deeper on NCT03101163.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03101163.